The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study

Wongsakorn Luangphiphat; Pinidphon Prombutara; Praewpannarai Jamjuree; Chantanapa Chantarangkul; Porntipha Vitheejongjaroen; Chantaluck Muennarong; Krittapat Fukfon; Manasvin Onwan; Malai Taweechotipatr

doi:10.1371/journal.pone.0317202

journal article Open Access Jan 10, 2025

The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study

Wongsakorn Luangphiphat Pinidphon Prombutara

Praewpannarai Jamjuree Chantanapa Chantarangkul Porntipha Vitheejongjaroen Chantaluck Muennarong Krittapat Fukfon Manasvin Onwan

Malai Taweechotipatr

PLoS ONE Vol. 20 No. 1 pp. e0317202 · Public Library of Science (PLoS)

View at Publisher Save 10.1371/journal.pone.0317202

Abstract

Modern treatment, a healthy diet, and physical activity routines lower the risk factors for metabolic syndrome; however, this condition is associated with all-cause and cardiovascular mortality worldwide. This investigation involved a randomized controlled trial, double-blind, parallel study. Fifty-eight participants with risk factors of metabolic syndrome according to the inclusion criteria were randomized into two groups and given probiotics (Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1) (n = 31) or a placebo (n = 27). The participants had a mean age of 42.29 ± 7.39 and 43.89 ± 7.54 years in the probiotics and placebo groups, respectively. Stool samples, anthropometric data, and blood chemistries were taken at baseline and at 12 weeks. The primary outcome was achieved by the probiotics group as their low-density lipoprotein-cholesterol level dramatically lowered compared to the placebo group (the difference was 39.97 ± 26.83 mg/dl, p-value <0.001). Moreover, significant reductions in body weight, body mass index, waist circumference, systolic blood pressure, and total cholesterol were observed in the volunteers treated with probiotics compared to the placebo. In the gut microbiome analysis, the results showed statistically significant differences in the beta diversity in the post-intervention probiotics group. Blautia, Roseburia, Collinsella, and Ruminococcus were among the gut microbiomes that were more prevalent in the post-intervention probiotics group. In addition, this group exhibited increases in the predicted functional changes in ATP-binding cassette (ABC) transporters, as well as ribonucleic acid transport, the biosynthesis of unsaturated fatty acids, glycerophospholipid metabolism, and pyruvate metabolism. In conclusion, this research demonstrated that the probiotics L. paracasei MSMC39-1 and B. animalis TA-1 have the efficacy to lower risk factors associated with metabolic syndrome.

Topics

No keywords indexed for this article. Browse by subject →

References

122

[1]

PL Huang "A comprehensive definition for metabolic syndrome." Dis Model Mech (2009) 10.1242/dmm.001180

[2]

JD Tune "Cardiovascular consequences of metabolic syndrome." Transl Res (2017) 10.1016/j.trsl.2017.01.001

[3]

MK Bhatnagar "Assessment of insulin resistance using surrogate markers in patients of metabolic syndrome. Diabetes Metab Syndr" Clin Med Rev (2011)

[4]

P Perez-Martinez "Lifestyle recommendations for the prevention and management of metabolic syndrome: An international panel recommendation." Nutrition Reviews (2017) 10.1093/nutrit/nux014

[5]

W Li "Association between metabolic syndrome and mortality: Prospective cohort study." JMIR Public Health Surveill (2023) 10.2196/44073

[6]

A Nesci "Gut microbiota and cardiovascular disease: Evidence on the metabolic and inflammatory background of a complex relationship" Int J Mol Sci (2023) 10.3390/ijms24109087

[7]

M. Breban "Gut microbiota and inflammatory joint diseases" Joint Bone Spine (2016) 10.1016/j.jbspin.2016.04.005

[8]

Human gut microbiota in health and disease: Unveiling the relationship

Muhammad Afzaal, Farhan Saeed, Yasir Abbas Shah et al.

Frontiers in Microbiology 2022 10.3389/fmicb.2022.999001

[9]

WHW Tang "Gut microbiota in cardiovascular health and disease" Circ Res (2017) 10.1161/circresaha.117.309715

[10]

H Mostafavi Abdolmaleky "Gut microbiota dysbiosis, oxidative stress, inflammation, and epigenetic alterations in metabolic diseases." Antioxidants. (2024) 10.3390/antiox13080985

[11]

MW Rohr "Negative effects of a high-fat diet on intestinal permeability: A review." Adv Nutr (2020) 10.1093/advances/nmz061

[12]

PX Wang "Gut microbiota and metabolic syndrome" Chin Med J (2020) 10.1097/cm9.0000000000000696

[13]

PD Cani "Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity." Gut Microbes. (2012) 10.4161/gmic.19625

[14]

T Li "Milk fat globule membrane supplementation modulates the gut microbiota and attenuates metabolic endotoxemia in high-fat diet-fed mice" J Funct Foods (2018) 10.1016/j.jff.2018.05.038

[15]

The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic

Colin Hill, Francisco Guarner, Gregor Reid et al.

Nature Reviews Gastroenterology & Hepatology 2014 10.1038/nrgastro.2014.66

[16]

C. De Simone "The unregulated probiotic market" Clin Gastroenterol Hepatol (2019) 10.1016/j.cgh.2018.01.018

[17]

RCR Martinez "Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: An update for current perspectives and future challenges" Br J Nutr (2015) 10.1017/s0007114515003864

[18]

S Ding "The impact of probiotics on gut health via alternation of immune status of monogastric animals" Anim Nutr (2021) 10.1016/j.aninu.2020.11.004

[19]

LG Bermudez-Humaran "Exploring the interaction and impact of probiotic and commensal bacteria on vitamins, minerals and short chain fatty acids metabolism" Microb Cell Fact (2024) 10.1186/s12934-024-02449-3

[20]

EH Ezenabor "Gut microbiota and metabolic syndrome: Relationships and opportunities for new therapeutic strategies." Scientifica (2024) 10.1155/2024/4222083

[21]

C Guazzelli Marques "Weight loss probiotic supplementation effect in overweight and obesity subjects: A review." Clin Nutr. (2020) 10.1016/j.clnu.2019.03.034

[22]

G John "Dietary alteration of the gut microbiome and its impact on weight and fat mass: A systematic review and meta-analysis" Genes (2018) 10.3390/genes9030167

[23]

PM Bock "Understanding how pre- and probiotics affect the gut microbiome and metabolic health" Am J Physiol Endocrinol Metab (2024) 10.1152/ajpendo.00054.2024

[24]

PS Lim "Cholesterol homeostasis associated with probiotic supplementation in vivo" J Appl Microbiol (2020) 10.1111/jam.14678

[25]

BK Thakur "Live and heat-killed probiotic Lactobacillus casei Lbs2 protects from experimental colitis through Toll-like receptor 2-dependent induction of T-regulatory response" Int Immunopharmacol (2016) 10.1016/j.intimp.2016.03.033

[26]

AFG Cicero "Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: A randomized placebo-controlled clinical trial" Eur J Nutr (2021) 10.1007/s00394-020-02271-8

[27]

P Jamjuree "Characterization and product formulation of cholesterol-lowering probiotic strains for prevention of metabolic syndrome." J Med Health Sci [Internet]. (2023)

[28]

N Puttarat "Beneficial effects of indigenous probiotics in high-cholesterol diet-induced hypercholesterolemic rats." Nutrients (2023) 10.3390/nu15122710

[29]

B Ladda "In vitro modulation of tumor necrosis factor α production in THP-1 cells by lactic acid bacteria isolated from healthy human infants" Anaerobe (2015) 10.1016/j.anaerobe.2015.03.002

[30]

American Diabetes Association "Diagnosis and classification of diabetes mellitus." Diabetes Care (2014) 10.2337/dc14-s081

[31]

B Williams "2018 ESC/ESH guidelines for the management of arterial hypertension" Eur Heart J (2019)

[32]

S Wilson "Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk." J Clin Hypertens (Greenwich). (2021) 10.1111/jch.14186

[33]

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Salim Yusuf, Steven Hawken, Stephanie Ounpuu et al.

The Lancet 2004 10.1016/s0140-6736(04)17018-9

[34]

A Costabile "An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults." PLoS ONE. (2017) 10.1371/journal.pone.0187964

[35]

MY Lim "Evaluation of fecal DNA extraction protocols for human gut microbiome studies" BMC Microbiol (2020) 10.1186/s12866-020-01894-5

[36]

AM García-Alegría "Quantification of DNA through the nanodrop spectrophotometer: Methodological validation using standard reference material and Sprague Dawley rat and human DNA. Abdel-Rehim M, editor" Int J Anal Chem (2020) 10.1155/2020/8896738

[37]

Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms

J Gregory Caporaso, Christian L Lauber, William A Walters et al.

The ISME Journal 2012 10.1038/ismej.2012.8

[38]

TC Lorenz "Polymerase chain reaction: Basic protocol plus troubleshooting and optimization strategies." J Vis Exp (2012)

[39]

T Naik "High-quality single amplicon sequencing method for illumina MiSeq platform using pool of ‘N’ (0–10) spacer-linked target specific primers without PhiX spike-in." BMC Genomics (2023) 10.1186/s12864-023-09233-4

[40]

JJ Kozich "Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform" Appl Environ Microbiol (2013) 10.1128/aem.01043-13

[41]

E Bolyen "Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2" Nat Biotechnol (2019) 10.1038/s41587-019-0209-9

[42]

PD Schloss "Amplicon sequence variants artificially split bacterial genomes into separate clusters." mSphere (2021) 10.1128/msphere.00191-21

[43]

MJ Anderson (2017)

[44]

A Dhariwal "Microbiomeanalyst: A web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data" Nucleic Acids Res (2017) 10.1093/nar/gkx295

[45]

GM Douglas "PICRUSt2 for prediction of metagenome functions" Nat Biotechnol (2020) 10.1038/s41587-020-0548-6

[46]

DH Parks "STAMP: Statistical analysis of taxonomic and functional profiles" Bioinformatics (2014) 10.1093/bioinformatics/btu494

[47]

StataCorp (2019)

[48]

W. Haynes (2013) 10.1007/978-1-4419-9863-7_1215

[49]

O Mhaimeed "The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better." Am J Prev Med (2024)

[50]

Y Zhang "Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events" JAMA Cardiol (2021) 10.1001/jamacardio.2021.3508

Showing 50 of 122 references

Metrics

6

Citations

122

References

Details

Published: Jan 10, 2025
Vol/Issue: 20(1)
Pages: e0317202
License: View

Authors

W

Wongsakorn Luangphiphat

P

Pinidphon Prombutara

P

Praewpannarai Jamjuree

C

Chantanapa Chantarangkul

P

Porntipha Vitheejongjaroen

C

Chantaluck Muennarong

Funding

Chiangmai Bioveggie and National Innovation Agency Award: PE0201-02-64-11-0252

Center of Excellent in Probiotics Srinakharinwirot University Award: 324/2565

Cite This Article

Wongsakorn Luangphiphat, Pinidphon Prombutara, Praewpannarai Jamjuree, et al. (2025). The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study. PLoS ONE, 20(1), e0317202. https://doi.org/10.1371/journal.pone.0317202

The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study

You May Also Like